183 related articles for article (PubMed ID: 21273176)
1. The potential application of zoledronic acid as anticancer therapy in patients with non-small-cell lung cancer.
Mahtani R; Khan R; Jahanzeb M
Clin Lung Cancer; 2011 Jan; 12(1):26-32. PubMed ID: 21273176
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of denosumab vs zoledronic acid for prevention of skeletal-related events in patients with solid tumors and bone metastases in the United States.
Stopeck A; Rader M; Henry D; Danese M; Halperin M; Cong Z; Qian Y; Dansey R; Chung K
J Med Econ; 2012; 15(4):712-23. PubMed ID: 22409231
[TBL] [Abstract][Full Text] [Related]
3. Clinical significance of zoledronic acid and strontium-89 in patients with asymptomatic bone metastases from non-small-cell lung cancer.
Wang Y; Tao H; Yu X; Wang Z; Wang M
Clin Lung Cancer; 2013 May; 14(3):254-60. PubMed ID: 23103352
[TBL] [Abstract][Full Text] [Related]
4. Under usage of zoledronic acid in non-small cell lung cancer patients with metastatic bone disease--a short communication.
Calderone R; Nimako K; Leary A; Popat S; O'Brien ME
Eur J Cancer; 2011 Jul; 47(11):1603-5. PubMed ID: 21684152
[TBL] [Abstract][Full Text] [Related]
5. Bisphosphonates in lung cancer: more than a palliative therapy?
Jahanzeb M; Hirsh V
Semin Oncol; 2010 Jun; 37 Suppl 1():S45-52. PubMed ID: 20682372
[TBL] [Abstract][Full Text] [Related]
6. Zoledronic acid in lung cancer with bone metastases: a review.
Isla D; Afonso R; Bosch-Barrera J; Martínez N
Expert Rev Anticancer Ther; 2013 Apr; 13(4):421-6. PubMed ID: 23560837
[TBL] [Abstract][Full Text] [Related]
7. The role of bisphosphonates in the management of advanced cancer with a focus on non-small-cell lung cancer. Part 2: Clinical studies and economic analyses.
Saba N; Khuri F
Oncology; 2005; 68(1):18-22. PubMed ID: 15775689
[TBL] [Abstract][Full Text] [Related]
8. Skeletal disease contributes substantially to morbidity and mortality in patients with lung cancer.
Hirsh V
Clin Lung Cancer; 2009 Jul; 10(4):223-9. PubMed ID: 19632938
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of zoledronic acid in the management of skeletal metastases in patients with lung cancer in France, Germany, Portugal, the Netherlands, and the United kingdom.
Joshi AD; Carter JA; Botteman MF; Kaura S
Clin Ther; 2011 Mar; 33(3):291-304.e8. PubMed ID: 21600384
[TBL] [Abstract][Full Text] [Related]
10. A case of bone, lung, pleural and liver metastases from renal cell carcinoma which responded remarkably well to zoledronic acid monotherapy.
Miwa S; Mizokami A; Konaka H; Izumi K; Nohara T; Namiki M
Jpn J Clin Oncol; 2009 Nov; 39(11):745-50. PubMed ID: 19808839
[TBL] [Abstract][Full Text] [Related]
11. Overall survival improvement in patients with lung cancer and bone metastases treated with denosumab versus zoledronic acid: subgroup analysis from a randomized phase 3 study.
Scagliotti GV; Hirsh V; Siena S; Henry DH; Woll PJ; Manegold C; Solal-Celigny P; Rodriguez G; Krzakowski M; Mehta ND; Lipton L; García-Sáenz JA; Pereira JR; Prabhash K; Ciuleanu TE; Kanarev V; Wang H; Balakumaran A; Jacobs I
J Thorac Oncol; 2012 Dec; 7(12):1823-1829. PubMed ID: 23154554
[TBL] [Abstract][Full Text] [Related]
12. Zoledronic acid: multiplicity of use across the cancer continuum.
Lipton A
Expert Rev Anticancer Ther; 2011 Jul; 11(7):999-1012. PubMed ID: 21806323
[TBL] [Abstract][Full Text] [Related]
13. Safety and efficacy of zoledronic acid rapid infusion in lung cancer patients with bone metastases: a single institution experience.
Kotteas E; Alamara C; Kiagia M; Pantazopoulos K; Boufas A; Provata A; Charpidou A; Syrigos KN
Anticancer Res; 2008; 28(1B):529-33. PubMed ID: 18383897
[TBL] [Abstract][Full Text] [Related]
14. Role of zoledronic acid in the setting of bone metastases from non-small-cell lung cancer.
Langer CJ
Clin Lung Cancer; 2005 Mar; 6(5):314-6. PubMed ID: 15845184
[TBL] [Abstract][Full Text] [Related]
15. Zoledronic acid is unable to induce apoptosis, but slows tumor growth and prolongs survival for non-small-cell lung cancers.
Li YY; Chang JW; Chou WC; Liaw CC; Wang HM; Huang JS; Wang CH; Yeh KY
Lung Cancer; 2008 Feb; 59(2):180-91. PubMed ID: 17900752
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of zoledronic acid in the treatment of bone metastases associated with lung cancer and other solid tumors.
Rosen LS
Semin Oncol; 2002 Dec; 29(6 Suppl 21):28-32. PubMed ID: 12584692
[TBL] [Abstract][Full Text] [Related]
17. Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, Phase III, double-blind, placebo-controlled trial.
Rosen LS; Gordon D; Tchekmedyian NS; Yanagihara R; Hirsh V; Krzakowski M; Pawlicki M; De Souza P; Zheng M; Urbanowitz G; Reitsma D; Seaman J
Cancer; 2004 Jun; 100(12):2613-21. PubMed ID: 15197804
[TBL] [Abstract][Full Text] [Related]
18. Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors.
Brown JE; Cook RJ; Major P; Lipton A; Saad F; Smith M; Lee KA; Zheng M; Hei YJ; Coleman RE
J Natl Cancer Inst; 2005 Jan; 97(1):59-69. PubMed ID: 15632381
[TBL] [Abstract][Full Text] [Related]
19. Emerging role of bisphosphonates in the clinic--antitumor activity and prevention of metastasis to bone.
Lipton A
Cancer Treat Rev; 2008; 34 Suppl 1():S25-30. PubMed ID: 18486347
[TBL] [Abstract][Full Text] [Related]
20. Optimal management of metastatic bone disease.
Major P
Eur J Oncol Nurs; 2007; 11 Suppl 2():S32-7. PubMed ID: 17804294
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
